**Robust deal flow through year-end underpins elevated trader expectations for additional IPOs before 2027.** As of late September 2026, multiple listings are scheduled or recently priced, including Amaero (Sep 24), ADARx Pharmaceuticals (Sep 25), Accelevation Holdings, and Oura (both Sep 30), alongside ongoing SPAC activity and a pipeline of biotech, AI-infrastructure, and consumer names. Q3 2026 delivered 31 U.S. IPOs raising $34.9 billion, led by SK hynix’s large offering, though smaller deals dominated after excluding megacaps. Market-implied odds reflect this momentum despite headwinds from 19-year-high Treasury yields, resumed rate-hike expectations, and caution around AI capital spending that has postponed some high-profile candidates like OpenAI toward 2027. Key near-term catalysts include upcoming pricing windows, FOMC communications on policy, and any revisions to forward economic data that could reopen or further constrain the window.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedPerplexity remains private with no confirmed IPO before the deadline
Available reporting continues to describe Perplexity as private and its CEO’s stated target as 2028. No official IPO completion or filing by the market deadline was found in the supplied material, supporting the low endpoint price.

































Beware of external links.
Beware of external links.
Frequently Asked Questions